Abbott (NYSE:ABT) announced today that it received FDA clearance for its FreeStyle Libre 2 iOS application for use with compatible iPhones.
The Abbott Park, Ill.-based company designed the new FreeStyle Libre 2 app to enable users to get glucose readings directly on their iPhones without the use of a reader, allowing caregivers to remotely monitor glucose readings and get real-time alarms through the LibreLinkUp app.
Get the full story at our sister site, Drug Delivery Business News.